Clinical Trial Update: First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers [Phase 1]

View source ↗

Summary

The first-in-human Phase 1 study of ATX-559, an oral DHX9 inhibitor from Accent Therapeutics, has been terminated; the trial included patients with advanced sol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colon Cancer
• Colorectal Cancer
• Endometrial Cancer
• Rectal Cancer

Drugs mentioned

• ATX-559 (ATX-559)

Snippet

Sponsor: Accent Therapeutics | Conditions: Advanced Solid Tumors, Breast Cancer Recurrent | Phase 1 | Status: TERMINATED